The 2014 Fall Edition of the PHSI Newsletter is now available to read here. This issue of the newsletter discusses the challenges faced by the FDA when naming biosimilars and also takes a look at the implications of increasing prescription compounds. If you would like to receive the newsletter electronically, click here to sign up for our e-Newsletter Mailing List!